Glucagon-like Peptide-1 (GLP-1) and neurotransmitters signaling in epilepsy: An insight review
Koshal P, Jamwal S, Kumar P. Glucagon-like Peptide-1 (GLP-1) and neurotransmitters signaling in epilepsy: An insight review. Neuropharmacology 2017, 136: 271-279. PMID: 29129776, DOI: 10.1016/j.neuropharm.2017.11.015.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1Neurotransmitter systemsAltered neurotransmittersProtective roleNeurological disordersNeurotransmitter signalingProgression of seizuresGABAergic neurotransmitter systemAnti-epileptic drugsManagement of epilepsyGLP-1 analoguesGLP-1 receptorTreatment of epilepsyFuture drug therapiesOnly symptomatic reliefBasic pathogenic mechanismsPrevalent neurological disordersPreproglucagon neuronsSymptomatic reliefGlutamatergic systemPathophysiological mechanismsDrug therapyRisk factorsMetabolic impairmentPeptide-1Animal Models of Epilepsy
Koshal P, Jamwal S, Akula K, Bansal P. Animal Models of Epilepsy. 2017, 59-78. DOI: 10.1007/978-981-10-5981-0_5.Peer-Reviewed Original ResearchCentral nervous systemAntiepileptic drugsEpileptic seizuresPrinciple inhibitory neurotransmitterDevelopment of epilepsyLong-term outcomesType of epilepsyExcessive electrical dischargesGABAergic axon terminalsTreatment of epilepsyCommon neurological disorderPopulations of neuronsAmino butyric acidFrequent seizuresGABAB receptorsSecondary complicationsInhibitory neurotransmitterGABAA receptorsMotor disordersAxon terminalsEpileptic patientsHealthcare costsAnimal modelsNervous systemNeonatal stage